Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
Delcath Systems to Host First Quarter 2026 Earnings Call
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
Contrasting Delcath Systems (NASDAQ:DCTH) & ADB International Group (OTCMKTS:EQUR)
Delcath Systems, Inc. (NASDAQ:DCTH) Receives $22.50 Average PT from Analysts
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
Delcath: Fundamentals Intact, Despite Share Price Weakness
Delcath Systems Q4 Earnings Call Highlights
Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
Micron Solutions (OTCMKTS:MICR) and Delcath Systems (NASDAQ:DCTH) Critical Review
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Set Delcath Systems, Inc. (NASDAQ:DCTH) PT at $22.40
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
Delcath Systems (NASDAQ:DCTH) vs. AngioDynamics (NASDAQ:ANGO) Head-To-Head Survey
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
Delcath: Temporary Headwinds Are No Cause For Concern
Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Q3 Earnings Match Estimates
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
Analysts Set Delcath Systems, Inc. (NASDAQ:DCTH) Target Price at $24.00
Delcath Systems to Host Third Quarter 2025 Earnings Call
Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript
Delcath: Large Upside With Limited Downside Risk
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript
Delcath (DCTH) Q2 Revenue Jumps 210%
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems to Host Second Quarter 2025 Earnings Call